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Abstract
Background: The impact of early postnatal androgen exposure on female laryngeal tissue may depend on certain
characteristics of this exposure. We assessed the impact of the dose, duration, and timing of early androgen exposure on
the vocal development of female subjects who had been treated for adrenocortical tumor (ACT) in childhood.
Methods: The long-term effects of androgen exposure on the fundamental vocal frequency (F0), vocal pitch, and final
height and the presence of virilizing signs were examined in 9 adult (age, 18.4 to 33.5 years) and 10 adolescent (13.6 to 17.8
years) female ACT patients. We also compared the current values with values obtained 0.9 years to 7.4 years after these
subjects had undergone ACT surgery, a period during which they had shown normal androgen levels.
Results: Of the 19 subjects, 17 (89%) had been diagnosed with ACT before 4 years of age, 1 (5%) at 8.16 years, and 1 (5%) at
10.75 years. Androgen exposure (2 to 30 months) was sufficiently strong to cause pubic hair growth in all subjects and
clitoromegaly in 74% (14/19) of the subjects, but did not reduce their height from the target value. Although androgen
exposure induced a remarkable reduction in F0 (132 Hz) and moderate pitch virilization in 1 subject and partial F0
virilization, resulting in F0 of 165 and 169 Hz, in 2 subjects, the majority had normal F0 ranging from 189 to 245 Hz.
Conclusions: Female laryngeal tissue is less sensitive to androgen exposure between birth and adrenarche than during
other periods. Differential larynx sensitivity to androgen exposure in childhood and F0 irreversibility in adulthood are age-,
concentration-, duration-, and timing-dependent events that may also be affected by exposure to inhibitory or stimulatory
hormones. Further studies are required to better characterize each of these factors.
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Introduction
Clinicians who are not voice specialists frequently examine
vocal pitch as a proxy of perceptual vocal characteristics [1]. A
more useful approach is to measure fundamental voice frequency
(F0) in terms of cycles/sec (Hz), which provides a more precise
estimation of the factors that cause linear changes in vocal
characteristics. The female larynx is very sensitive to fluctuations
in androgen levels, which decrease F0 to a level 1/3rd lower than
that of a child during puberty [2–4]. After puberty, the F0 of
nonsmoking females reaches a plateau until the fifth decade, when
it undergoes a slight decrease, most likely due to an increased
testosterone-to-estrogen ratio after menopause [2,5].
The mean F0 of the mature voice of women in southern Brazil,
the majority of whom are of European descent, is 211 Hz [4]. In
women undergoing androgen therapy, reduction in F0 or vocal
pitch has been shown to be a function of androgen and
testosterone levels [6]. Indeed, research has found that only 1
injection of testosterone may cause irreversible vocal changes in
women [7], with 1 study of 38 women with CAH aged 18 to 63
years showing that these women had a significantly lower F0 than
normal controls [8].
Although the greatest F0 reduction in men occurs during
puberty, male F0 may still continue to decrease until the fourth
decade, and may subsequently increase during the sixth decade
[2,9,10]. Modifications in laryngeal size in adult men may also be
caused by congenital growth hormone deficiency (GHD), which
leads to development of an F0 of between 174 and 266 Hz, a range
typical of normal adult women. The timing of GHD is a de-
termining factor in pitch alteration, with research showing that
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patients who experience adult-onset GHD between 31 and 40
years of age have a normal male pitch and an F0 varying from 117
to 154 Hz [11].
The incidence of ACT in children younger than 15 years is at
least 15 times higher in southern Brazil than that in the United
States or Europe [12–15]; this trend is particularly prominent
among girls younger than 4 years of age [15–17]. One major issue
in this regard is the controversy surrounding the conditions under
which virilization is irreversible in patients with pathological
conditions. Therefore, this study aimed to identify the impact of
variations in the intensity, duration, and timing of early postnatal
androgen exposure on the final height, F0, and vocal pitch of
female subjects. These female subjects had presented with ACT
early in life and were subsequently reevaluated. As such, this is the
first study to present data on the long-term impact of limited
exposure to high androgen levels at a very young age among
female subjects.
Materials and Methods
Subjects
Before the study initiation, approval for this study was obtained
by the Ethics Committee of Pequeno Prı´ncipe Hospital and from
each subject or, if the subject was a minor, from a parent, by
requesting the subject or her parent to read and sign the consent
form. Thirty female patients who had completed more than 11.4
years of ACT treatment at the main reference hospitals of
Curitiba, the capital of Parana´ State, were invited to participate.
Of the 22 volunteers who had ACT and agreed to participate, 19
met the inclusion criteria of (1) having experienced virilizing
symptoms related to a previously treated adrenocortical tumor in
the pre-pubertal stage, with 16 having been treated for adreno-
cortical carcinoma and 3 for adenoma; (2) being at least 13 years
of age, and (3) having experienced menarche at least 2 years prior
to study initiation. All 19 also met none of the exclusion criteria of
(1) being a smoker, (2) having undergone vocal treatment, (3)
currently experiencing edema of the vocal folds for other reasons,
or (4) having experienced prolonged androgen exposure due to
multiple ACT recurrence. Of the 19 subjects, whose age ranged
from 13.6 to 33.5 years, 9 were adult females ranging from 18.4 to
33.5 years of age and 10 were adolescents ranging from 13.6 to
17.8 years of age. Comparison of actual height and predicted
target height (TH) and vocal assessment were conducted for all
subjects.
Of the 19 subjects, 17 (89%) had been diagnosed with ACT
before 4 years of age, 1 (5%) at 8.16 years, and 1 (5%) at 10.75
years. The majority (15/19, 78%) had participated in a molec-
ular analysis of ACT patients in which they had tested positive
for the germline R337H mutation in the TP53 gene [12,13,18–
20]. Three of the participants (16%) showed a combination of
virilization and Cushing’s syndrome (CS) at the time of ACT
diagnosis. The characteristics of external genitalia at early ages
and the duration over which the patients showed clinical
manifestations of androgen-induced virilizing syndrome before
ACT diagnosis, which ranged from 2 to 30 months, were
determined from medical records. A control group composed of
6 female siblings of the participants, whose age ranged from
17.5 to 26.5 years, was recruited to serve as representatives of
the normal female population. In addition, the F0 data obtained
from the normal female population in this region by one of the
coauthors served as valuable control data (ML’s thesis, 2003,
reference 4).
Vocal Recordings
Vocal recordings were conducted in a speech pathology
outpatient clinic room free of noise and echo. While seated with
her feet on the ground, her posture upright, and a digital recorder
(IMP Optimus Unidirectional Microphone 600V; Philippines)
placed 10 cm from her mouth at a 90u angle from her chin, each
participant was recorded continuously vocalizing the ‘‘e’’ vowel
sound while counting from 1 to 20. In accordance with the
observations of recording manufacturers and other authors,
sustained vocalization of the ‘‘e’’ vowel sound was selected from
among all possible vocalizations because it provides for the best
possible capture [8,21–24]. The software packages used for
acoustic measurement were the Software Quality Voice Files for
Vowels program and the Analysis of Voice at the Numbers
program (VoxMetriaH version 4.6). Perceptual evaluation of pitch
was conducted by the same clinic and vocal recordings were
reviewed by evaluators blinded to the study protocol at a second
voice laboratory located at the Federal University of Sa˜o Paulo
(UNIFESP).
The F0 values were compared to the results of previous analyses
of recordings of 11 subjects, which had been made from 0.9 years
to 7.4 years after these subjects had undergone ACT surgery;
during this period, these subjects had presented with normal
androgen levels [4]. Although 1 participant had experienced local
relapse several months after removal of the primary ACT, she had
experienced no metastasis and been successfully treated with
chemotherapy. Qualitative evaluation of voice was also conducted
by 1 physician and 2 speech pathologists previously trained to
conduct vocal ratings, who independently evaluated vocal pitch by
rating the tone as manifesting mild virilization (+), moderate
virilization (++), or a typical male pitch (+++). Laryngoscopy and
vocal analysis were performed simultaneously with F0 and pitch
evaluation to monitor for potential laryngeal pathology.
Statistical Analysis
Using reference population data from the National Center for
Health Statistics (NCHS) [25], each participant’s height value was
transformed to an actual height Z-score (the standard deviation
score of the mean) and the value of the participant’s parent’s
height was used to calculate her TH Z-score [26,27]. Comparison
of the subject’s actual Z-score and TH Z-score was performed
using the paired Student’s t-test for dependent samples, with a final
height Z-score up to 1.0 standard deviation above or below the
target height Z-score considered an indicator of accordance with
the genetic pattern in height [28].
Results
Physical Examination
None of the subjects had experienced any pathological
condition other than ACT or taken any anabolic steroids. At
ACT diagnosis, all the subjects (19/19) presented with pubic hair
growth and the majority (14/19, 74%) presented with clitorome-
galy. In addition, 3 subjects, patients 1, 4, and 6, presented with
signs of CS, specifically with virilizing signs, since 8, 4, and 15
months before diagnosis, respectively, and these signs had been
confirmed to be CS indicators by subsequent measurement of
mildly or modestly elevated cortisol levels. The height of all the
subjects fell within the 50th and 75th percentiles, corresponding to
their familial TH, including that of the 1 participant (subject 14)
who presented with the lowest F0 (132 Hz) and moderate pitch
virilization.
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Vocal Characteristics
As previously described, 57% (11/19) of the participants had
previously participated in an analysis of F0 values obtained from
0.9 years to 7.4 years after ACT surgery. At this early age, 54%
(6/11) had presented with a normal F0 and 45% (5/11) had F0
significantly lower than the expected F0 for their chronological
age. This reduction in F0 was found to be inversely correlated
(p,0.05) with Tanner stage [4], which was used as a parameter of
accumulated androgen effect until ACT diagnosis.
Table 1 also presents the initial F0 of the subjects for whom data
were available. As can be observed, initial data were available for
only 11 of the subjects because several patients did not survive,
experienced multiple recurrences, or were not eligible for study
inclusion. The reliability of the instrumental measure for F0 was
found to be more accurate and quantitative than the subjective
evaluation (pitch). Mild or moderate virilization of pitch was
observed in the 4 subjects (subjects 7, 10, 14, and 18) who had
presented with the lowest F0 (165, 169, 132, and 189 Hz,
respectively), although subject 18 had presented with an F0 within
the lower limit of normality for females. Investigation of the extent
to which the marked reduction in F0 was irreversible, which was
performed by measurement of F0 more than 11 years later,
indicated that 3 subjects (subjects 8, 9, and 11) experienced
complete recovery of F0 and 2 subjects (subjects 7 and 10)
experienced only partial recovery, which accounted for the mild
pitch virilization in these subjects (Table 1). Interestingly, the F0 of
patient 10 had increased from 111 Hz to 169 Hz. One adult
subject (subject 14) with an F0 typical of that of males (132 Hz)
had been diagnosed with ACT at the age of 8.16 years and had
experienced virilizing syndrome for 2.5 years before ACT
diagnosis. However, as shown in Table 1, the observed reduction
in F0 in children only 0.9 years to 7.4 years after ACT treatment is
not a permanent effect leading to virilized F0 in mature subjects.
Sixteen (16/19, 84%) subjects had been diagnosed with ACT
before 4 years of age and had experienced virilizing syndrome for
2 to 17 months. One subject (1/19, 5%) who had undergone 8
months of androgen exposure before diagnosis at the age of 10.7
years was found to have a normal adult female F0 comparable to
that of most cases in the present study (16/19), the control group
(Table 2), or the control group previously described [4].
Discussion
Increased production of sex hormones in normal female subjects
during adrenarche and gonadarche induces growth of the larynx,
causing a rapid decrease in vocal pitch. Despite knowledge of this
phenomenon, little is known regarding the sensitivity of the female
larynx to androgen exposure during the pre-pubertal stage. This
knowledge gap is primarily due to the absence of F0 analysis not
only in the rare cases of childhood ACT [15,16], but also in the
few cases of childhood virilization caused by topical exposure
(usually accidental) to testosterone in the form of gels or patches
[29–31]. To our knowledge, this study is the first long-term
analysis of F0 in female patients exposed to high levels of
androgens at a very young age. We examined the effect of the
timing of this exposure, specifically whether androgen exposure
causes significant virilization during the pre-pubertal period
(ranging from few months after birth to adrenarche).
Due to the fact that survivors of multiple ACT recurrence were
excluded from the study because of prolonged androgen exposure,
as were smokers and patients who presented with signs of
inflammatory throat lesions, as well as the existence of a low
ACT survival rate [16] and follow-up losses, only 19 ACT patients
were eligible for study participation. Nevertheless, the foremost
research goal–determination of the impact of androgen exposure
leading to the development of remarkable pre-pubertal virilizing
signs on long-term (adult or adolescent) female F0–was achieved.
All the subjects (19/19) demonstrated a good understanding of
ACT signs and symptoms, especially due to their participation in
previous studies [12,13,32]. The variables of dose, timing, and
duration of androgen exposure were all found to be determinants
of virilization in the subjects, of whom 18 had experienced
virilization during the pre-pubertal stage and 1 during puberty.
Virilization was remarkable because of different degrees of pubic
hair growth (19/19, 100%) and its association with clitoral
enlargement in the majority of the subjects (14/19, 74%). All the
subjects reported that their medical history had been uneventful
after ACT treatment, and most reported that their clitoris had
partially returned to normal size, although this parameter was not
reevaluated in the most recent physical exam.
Although all the subjects had experienced a relatively long
period (2 to 30 months) of androgen exposure in childhood, the
exposure had not been sufficiently strong to cause loss of TH in
any of the subjects. Furthermore, the observed decrease in F0 in
45% (5/11) of the subjects within 0.9 to 7.4 years after tumor
resection, i.e., after normalization of androgen levels [4], had
subsequently recovered to normal values in 3 cases, and only 18%
(2/11; subjects 7 and 10) presented with partial virilization of F0
(165 and 169 Hz, respectively) and mild virilization of pitch.
Interestingly, 1 of these 2 cases (1/11) had presented with a typical
adult male F0 in childhood, suggesting that F0 may also be
partially recovered (from 111 Hz to 169 Hz) in the absence of any
treatment. Observation of mild or moderate virilization of pitch
observed in 4 participants was consistent with the lowest detected
F0, which ranged from 189 to 132 Hz. However, as expected, the
method used to measure F0 was more reliable (and quantitative)
than that used to evaluate pitch.
Although F0 has previously been investigated in female subjects
with CAH [8], these subjects may have been periodically exposed
to increased levels of androgens due to suboptimal treatment with
glucocorticoids [33], making it difficult to identify the timing and
duration of androgenic effects and making these subjects less than
ideal models. Figure 1 describes the timing and degrees of
androgen exposure (Tanner stage) as a reflection of the intensity of
the accumulated androgen effect. The determinants of laryngeal
tissue sensitivity to androgens and extent of differentiation shown
in Figure 1 were defined on the basis of the results of this study and
previous studies [1,3,4,8,9,10]. Lack of analysis regarding early
androgen exposure, particularly during the initial development of
ACT symptoms, combined with differences found among the
types of androgens examined has prevented systematic comparison
Table 2. F0 and vocal pitch of control group.
Subject Age (years) F0 Vocal pitch
1 21.5 215.3 F
2 23.9 202.4 F
3 17.5 219.7 F
4 26.5 244.5 F
5 26.1 231.2 F
6 21.2 207.3 F
Mean 22.8 220.1
SD 3.3 15.6
doi:10.1371/journal.pone.0050242.t002
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Figure 1. A flow chart summarizing the results of this and other studies investigating the postnatal periods of lowest and greatest
larynx sensitivity to androgen exposure and the mechanism of vocal development in response to this exposure. Pink curves
correspond to female F0 spectra and blue curves to male F0 spectra. (1) Normal development of F0 differentiation in males and females. Adrenarche
and activation of the hypothalamus–pituitary–gonadal axis (gonadarche) are the main events leading to attainment of adult vocal patterns. At
puberty, the larynx, vocal folds, and vocal tract (e.g., the resonance tube up to the oral cavity) acquire increased mass, leading to variable degrees of
F0 reduction in men at adrenarche and gonadarche and to partial reduction in women at adrenarche. F0 decreases and then stabilizes between the
ages of 14 and 18 years. Mean F0, which is shown for normal male and female Brazilian subjects [4], slightly decreases with age, as was shown in
a study of normal Swedish women [2] and in other studies (Hollien and Shipp, 1972; Stoicheff, 1981; Hollien et al., 1994), due to steroids and other
factors. (2) A hypothesis based on the study results postulating that androgen exposure during pre- and post-pubertal stages in CAH females causes
fluctuations in androgen levels and permanent virilization of F0. (3) A good marker identified for the accumulated androgen effect (represented by
Tanner stage) is shown for all ACT cases. Each full dot represents 4 months of androgen exposure. Androgen exposure during the pre-pubertal stage
leading to decreased F0 was found in only 3 ACT cases (3/19; 15.7%), leading to development of the hypothesis that laryngeal tissue has a low level of
sensitivity to androgen exposure during the first 5 postnatal years in females.
doi:10.1371/journal.pone.0050242.g001
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of hormone levels. Despite this challenge, the findings of this study
reveal the differences between the impact of ACT and CAH,
specifically that androgen exposure during early childhood is less
likely to result in an irreversibly virilized F0, and any significant
reductions in F0 at an early age are likely to be partially reversed
by increases to a normal F0 between childhood and adulthood.
Previous authors have proposed the existence of an androgenic
effect that includes the development of increased mass in laryngeal
tissue. Current knowledge of the mechanism by which steroids
induce sexual differentiation of vocal production at the brain level
is limited to animal models, particularly songbirds [34] and female
African clawed frogs (Xenopus laevis) [35,36]. The female laryngeal
muscle differs from the male laryngeal muscle [37], as most female
laryngeal neuromuscular synapses are stronger than the corre-
sponding male synapses [38–40]. At the CNS level, these
differences are responsible for generating sexually dimorphic
vocalizations, which are recorded in motor neurons [35].
The study data shown in Figure 1 support the hypothesis that
a period of low sensitivity in laryngeal tissue exists between birth
and adrenarche. The experience of subject 14, who had developed
ACT at the onset of or before adrenarche, with her parents first
reporting virilizing signs when she was less than 6 years old,
provides particular evidence of this phenomenon. Moreover,
subject 14 had also been exposed to particularly high levels of
androgens for a prolonged period lasting until close to the onset of
adrenarche, which, being a period of tissue maturation in the
larynx, had increased the probability that she would experience
vocal virilization.
As shown in Table 1, 3 subjects presented with CS, as
confirmed by measurement of mild to modest elevations in cortisol
levels. However, it is unclear whether the elevation in serum
cortisol concentration impacts the effects of androgen on laryngeal
tissue. Therefore, further studies are necessary to evaluate the
effects of the concentration, duration, and timing of cortisol
exposure on the F0 of children with CS.
In conclusion, the findings of this study support the hypothesis
that female laryngeal tissue is less sensitive to androgen exposure
between birth and adrenarche. Particularly compelling was the
finding of F0 virilization in only 1 subject, who had experienced
androgen exposure immediately before the period at which
adrenarche typically begins and for a longer duration (30 months)
than that in the other subjects. Although a subject who had
experienced androgen exposure during adrenarche had sub-
sequently developed a normal female F0, she had also experienced
elevated cortisol levels during the same period (8 months before
ACT diagnosis) based on the reported clinical signs. Thus, the
possibility that cortisol production had exerted an inhibitory effect
on androgen exposure cannot be ruled out in this case.
Furthermore, it was not possible to define the exact contribution
of ACT androgens, which most likely acted during the final stages
of adrenarche. The findings also indicate that differential larynx
sensitivity to androgens exposure in childhood and F0 irrevers-
ibility later in adulthood are age-, androgen concentration-,
duration-, and timing-dependent events that may also be affected
by exposure to inhibitory or stimulatory hormones, such as
glucocorticoids. Further studies are now required to better
characterize each of these factors.
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